异环磷酰胺联合依托泊苷在多线难治性乳腺癌中的疗效及安全分析(3)
 |
| 第1页 |
参见附件(4293KB，5页)。
[3] 罗湘,史艳侠,李志铭,等.三阴乳腺癌的临床病理特征和预后分析[J].中国癌症杂志,2009,19(7):517-22.
[4] Sirohi B, Arnedos M, Popat S, et al. Platinum-Based Chemotherapy in Triple-Negative Breast Cancer [J]. Ann Oncol, 2008,19(11):1847-1852.
[5] Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy [J]. J Natl Cancer Inst,2004,96:1659-1668.
[6] Bisagni G, Boni C, Manenti AL, et al. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study [J]. Tumori,1998,84(6):659-61.
[7] Aziz Z, Rehman A, Qazi S. Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy[J]. Cancer Chemother Pharmacol,1999,44(Suppl):9-12.
[8] 渋谷昌彦.新的药物毒副反应判定标准:NCI-CTC2.0 版本[J].日本医学介绍,2001,22(11):483-486.
[9] Devita VT Jr, Hellman S, Rosenberg SA.Cancer: Principles and Practices of Oncology[M].5th ed. Philadelphia:Lippincott-Raven,1997:1541-57.
[10] Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer[J]. Ann Oncol,2009,20(11):1771-85.
[11] Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (XelodaR) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy[J]. Ann Oncol,2003,14(8):1227-1233.
[12] Martín M, Ruiz A, Muoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial [J]. Lancet Oncol,2007,8(3):219-225 ......
您现在查看是摘要介绍页，详见PDF附件(4293KB，5页)。